Theriva Biologics (TOVX) director awarded 75,000 stock options at $0.241

Rhea-AI Filing Summary

Theriva Biologics, Inc. reported an insider equity award to one of its directors. The Form 4 shows a grant of 75,000 stock options with an exercise price of $0.241 per share on 01/05/2026. These options become exercisable starting 02/01/2026 and expire on 01/04/2033. According to the footnote, the options vest on a pro rata monthly basis over 12 months, meaning the director earns a portion of the grant each month during the first year.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Kraws Jeffrey J

(Last) (First) (Middle)

C/O THERIVA BIOLOGICS, INC., 9605

MEDICAL CENTER DRIVE, SUITE 270

(Street)

ROCKVILLE MD 20850

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Theriva Biologics, Inc. [ TOVX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$0.241	01/05/2026		A		75,000(1)		02/01/2026(1)	01/04/2033	Common Stock	75,000	$0	75,000	D

Explanation of Responses:

1. These stock options vest pro rata on a monthly basis over 12 months.

	/s/ Jeffrey J. Kraws	01/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Theriva Biologics (TOVX) report on this Form 4?

The company reported that a director received 75,000 stock options on 01/05/2026, as shown in Table II of the filing.

What is the exercise price of the Theriva Biologics (TOVX) stock options?

The stock options reported carry an exercise price of $0.241 per share.

When do the reported Theriva Biologics (TOVX) stock options vest?

The footnote states that the 75,000 stock options vest pro rata on a monthly basis over 12 months.

When do the Theriva Biologics (TOVX) options become exercisable and when do they expire?

The options become exercisable on 02/01/2026 and have an expiration date of 01/04/2033, as indicated in Table II.

What is the reporting person’s relationship to Theriva Biologics (TOVX)?

The filing indicates that the reporting person is a Director of Theriva Biologics, Inc.

Is this Theriva Biologics (TOVX) Form 4 filed for one or multiple reporting persons?

The form is indicated as being filed by one reporting person, according to the box checked in Item 6.